• Welcome

    AMPK Pharmaceuticals is an Australia biopharmaceutical company focussed on the treatment of inflammation

Our Focus

Our Osteoarthritis Treatment Technology

Our development-technology is designed to alleviate inammation and pain in Osteoarthritis, in addition to providing essential chondroprotective drugs to mitigate further joint-degeneration.

Read More

Osteoarthritis

Osteoarthritis aects over 650 million around the world and is the most common form of arthritis. It is often described as the 'wear and tear' of joints resulting from the gradual loss of cartilage. Aside from worsening pain, Osteoarthritis can lead to complete disability and currently no cure exists.

read more

Anti-inflammatory and chondroprotective therapeutics for Osteoarthritis

Target: AMPK

Anti-Inflammatories

Our novel approach of targeting AMPK to induce a localised anti-inammatory response is a key function of our technology. Aside from triggering an anti-inammatory response, our technology also encourages cell cleaning, energy control, weight loss with evidence of life-longevity.

Read More

Why Target AMPK?

AMPK as a target....

Read More

Chondroprotective Agents

Chondrocytes are the only cells found in healthy cartilage. These cells produce and maintain the cartilage matrix. In Osteoarthritis, the cartilage breaks down, causing pain, swelling and problems moving the joints. Our developed therapeutics are designed to combat this process.

read more

Re-purposing Approved Therapeutics

Re-purposing already-approved components within a novel formulation boasts a therapeutic with known toxicities, handling and anticipated shorter-development times. At AMPK Pharmaceuticals, we have identified a formulation of endogenous (naturally occurring) components for potentially treatment for OA.

read more
What is Osteoarthritis?

RSS Latest Research & Reviews

630+
Million People Affected by Osteoarthritis
15 %
Affected Worldwide
0
Known Cures

AMPK Pharmaceuticals Drug Development

Inflammation Market

Estimated: $110 billion (2020)

Osteoarthritis

Development
90%
Design
80%
Marketing
70%

Development Timeline

  1. December 2018

    Discovery of Powerful Anti-Inflammatory Active

    Key ingredient identified for AMPK-H310-9

  2. April 2019

    Formulation AMPK-H310-9 Identified

    Powerful anti-inflammatory & chondroprotective agent

  3. December 2019

    Formulation AMPK-H676-9 Identified

    Powerful anti-inflammatory & chondroprotective agent

  4. March 2020

    Planned biological testing studies

    In vivo & in vitro studies scheduled

For more information - get in touch!